Featured Research

from universities, journals, and other organizations

Scientists synthesize unique family of anti-cancer compounds

Date:
February 13, 2010
Source:
Yale University
Summary:
Scientists have streamlined the process for synthesizing a family of compounds with the potential to kill cancer and other diseased cells, and have found that they represent a unique category of anti-cancer agents.

Image of one of the kinamycin compounds synthesized by Yale researchers destroying ovarian cancer cells (the spherical objects) in less than 48 hours in lab tests.
Credit: Gil Mor

Yale University scientists have streamlined the process for synthesizing a family of compounds with the potential to kill cancer and other diseased cells, and have found that they represent a unique category of anti-cancer agents. Their discovery appears in this week's online edition of the Journal of the American Chemical Society.

The team studied a family of compounds known as the kinamycins, which are naturally produced by bacteria during metabolism and are known for their potent toxicity. For years scientists have guessed that a core structure common to the different compounds within the group was responsible for this toxicity. Until now, chemists could not study the core structure because there was no simple way to create it in the laboratory.

Now the Yale team has developed a new method to recreate this structure that allows them to synthesize the kinamycins with much greater efficiency than previously possible. While scientists have produced kinamycins in the laboratory in the past, the Yale team was able to halve the number of steps required to go from simple, easily obtainable precursors to the complete molecule -- from 24 down to 12.

"By shortening the synthesis we can now prepare these molecules in the quantities required for further studies, including animal studies and even clinical trials," said Seth Herzon, assistant professor of chemistry and lead author of the study.

Working with researchers at the Yale School of Medicine and the Yale Chemical Genomics Screening Facility, the team has begun testing several of the compounds against cancer cells, with promising preliminary results. Next, they will work to understand the exact mechanism that makes the compounds -- which are benign on their own -- highly toxic once they penetrate cells.

"The key to success will be whether we can develop selectivity -- whether we can kill cancer cells in the presence of non-cancerous tissue," Herzon said. "Based on what we already know about the chemical reactivity of these molecules, I'm optimistic we can do this."

The reactive core of the kinamycins also plays a key role in another compound the team is studying, called lomaiviticin A, which is even more toxic and could prove even more effective in destroying cancer cells. "Lomaiviticin A is the big fish. It's more potent than the kinamycins, but it's also much harder to synthesize," Herzon said.

Both the kinamycins and lomaiviticin A are unique in their toxicity profiles, Herzon said, representing a new category of anti-cancer agents.

"There's no close analogy to draw from to predict how these molecules will behave, which will make it especially interesting to see where this research takes us," Herzon said. "This research involves a lot of exciting chemistry, but it also has real applications in biology and human medicine."

Other authors of the study include Christina Woo, Liang Lu, Shivajirao Gholap and Devin Smith, all of Yale University.

Funding for this research was provided by Yale University and Eli Lilly.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christina M. Woo, Liang Lu, Shivajirao L. Gholap, Devin R. Smith and Seth B. Herzon. Development of a Convergent Entry to the Diazofluorene Antitumor Antibiotics: Enantioselective Synthesis of Kinamycin F. Journal of the American Chemical Society, 2010; 100208113952050 DOI: 10.1021/ja910769j

Cite This Page:

Yale University. "Scientists synthesize unique family of anti-cancer compounds." ScienceDaily. ScienceDaily, 13 February 2010. <www.sciencedaily.com/releases/2010/02/100212141106.htm>.
Yale University. (2010, February 13). Scientists synthesize unique family of anti-cancer compounds. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/02/100212141106.htm
Yale University. "Scientists synthesize unique family of anti-cancer compounds." ScienceDaily. www.sciencedaily.com/releases/2010/02/100212141106.htm (accessed July 25, 2014).

Share This




More Matter & Energy News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Europe's Highest Train Turns 80 in French Pyrenees

Europe's Highest Train Turns 80 in French Pyrenees

AFP (July 25, 2014) Europe's highest train, the little train of Artouste in the French Pyrenees, celebrates its 80th birthday. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
TSA Administrator on Politics and Flight Bans

TSA Administrator on Politics and Flight Bans

AP (July 24, 2014) TSA administrator, John Pistole's took part in the Aspen Security Forum 2014, where he answered questions on lifting of the ban on flights into Israel's Tel Aviv airport and whether politics played a role in lifting the ban. (July 24) Video provided by AP
Powered by NewsLook.com
Creative Makeovers for Ugly Cellphone Towers

Creative Makeovers for Ugly Cellphone Towers

AP (July 24, 2014) Mobile phone companies and communities across the country are going to new lengths to disguise those unsightly cellphone towers. From a church bell tower to a flagpole, even a pencil, some towers are trying to make a point. (July 24) Video provided by AP
Powered by NewsLook.com
Algonquin Power Goes Activist on Its Target Gas Natural

Algonquin Power Goes Activist on Its Target Gas Natural

TheStreet (July 23, 2014) When The Deal's Amanda Levin exclusively reported that Gas Natural had been talking to potential suitors, the Ohio company responded with a flat denial, claiming its board had not talked to anyone about a possible sale. Lo and behold, Canadian utility Algonquin Power and Utilities not only had approached the company, but it did it three times. Its last offer was for $13 per share as Gas Natural's was trading at a 60-day moving average of about $12.50 per share. Now Algonquin, which has a 4.9% stake in Gas Natural, has taken its case to shareholders, calling on them to back its proposals or, possibly, a change in the target's board. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins